A Modular Approach to Developing a Lentiviral Vector Platform

In this webinar, Andrew Moreo, Head of Process Development and Preclinical Manufacturing at Andelyn Biosciences, walks through how Andelyn has built and validated a modular, scalable lentiviral vector (LVV) manufacturing platform, from upstream production through final fill.

What you'll learn:

- How Andelyn's Curator® Platform applies Optimization-By-Design™ principles to balance process standardization with product-specific needs

- The analytical toolkit Andelyn has developed for LVV characterization, including physical titer (p24 ELISA), genomic titer (RT-qPCR), and functional titer (transduction assay)

- Upstream and downstream process development strategies for adherent and suspension LVV production

- Process recovery data from CellSTACK® and HYPERStack® scales, demonstrating platform robustness and scalability

- How key program factors such as indication, patient population, dosing, and regulatory strategy inform CDMO platform selection

In this webinar, Andrew Moreo, Head of Process Development and Preclinical Manufacturing at Andelyn Biosciences, walks through how Andelyn has built and validated a modular, scalable lentiviral vector (LVV) manufacturing platform, from upstream production through final fill.

What you'll learn:

- How Andelyn's Curator® Platform applies Optimization-By-Design™ principles to balance process standardization with product-specific needs

- The analytical toolkit Andelyn has developed for LVV characterization, including physical titer (p24 ELISA), genomic titer (RT-qPCR), and functional titer (transduction assay)

- Upstream and downstream process development strategies for adherent and suspension LVV production

- Process recovery data from CellSTACK® and HYPERStack® scales, demonstrating platform robustness and scalability

- How key program factors such as indication, patient population, dosing, and regulatory strategy inform CDMO platform selection

Please click here to be taken to the external link

In this webinar, Andrew Moreo, Head of Process Development and Preclinical Manufacturing at Andelyn Biosciences, walks through how Andelyn has built and validated a modular, scalable lentiviral vector (LVV) manufacturing platform, from upstream production through final fill.

What you'll learn:

- How Andelyn's Curator® Platform applies Optimization-By-Design™ principles to balance process standardization with product-specific needs

- The analytical toolkit Andelyn has developed for LVV characterization, including physical titer (p24 ELISA), genomic titer (RT-qPCR), and functional titer (transduction assay)

- Upstream and downstream process development strategies for adherent and suspension LVV production

- Process recovery data from CellSTACK® and HYPERStack® scales, demonstrating platform robustness and scalability

- How key program factors such as indication, patient population, dosing, and regulatory strategy inform CDMO platform selection

Please click here to be taken to the external linkDownload
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.